EGFR
Les inhibiteurs du récepteur du facteur de croissance épidermique (EGFR) sont des composés qui bloquent la signalisation de l'EGFR, un récepteur souvent surexprimé dans divers cancers et qui joue un rôle crucial dans l'angiogenèse. Les inhibiteurs de l'EGFR sont utilisés pour prévenir la croissance tumorale et les métastases en perturbant les voies qui favorisent la formation de vaisseaux sanguins dans les tumeurs. Ces inhibiteurs sont largement utilisés dans la recherche et le traitement du cancer. Chez CymitQuimica, nous offrons une sélection diversifiée d'inhibiteurs de l'EGFR de haute qualité pour soutenir vos recherches en oncologie et angiogenèse.
587 produits trouvés pour "EGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
HKI-357
CAS :HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.Formule :C31H29ClFN5O3Degré de pureté :99.91%Couleur et forme :SolidMasse moléculaire :574.05Ref: TM-T11569
2mgÀ demander1mg62,00€5mg125,00€1mL*10mM (DMSO)159,00€10mg188,00€25mg373,00€50mg540,00€100mg787,00€200mg1.035,00€(Z)-RG-13022
CAS :(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].Formule :C16H14N2O2Couleur et forme :SolidMasse moléculaire :266.29EGFR-IN-33
CAS :EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97EGFR-IN-32
CAS :EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formule :C31H34N6O3Couleur et forme :SolidMasse moléculaire :538.64PAT-505
CAS :PAT-505 is an autologous epidermal growth factor inhibitor.Formule :C23H18ClF2N3O2SDegré de pureté :98.84%Couleur et forme :SolidMasse moléculaire :473.92EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formule :C32H28BrF3N6O4SCouleur et forme :SolidMasse moléculaire :729.57BEBT-109
CAS :BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formule :C27H32N8O3Degré de pureté :97.26%Couleur et forme :SolidMasse moléculaire :516.6EGFR-IN-71
CAS :EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.Formule :C16H9ClIN3Couleur et forme :SolidMasse moléculaire :405.62EGFR-IN-36
CAS :EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97EGFR-IN-30
CAS :EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Formule :C28H33BrN7O2PCouleur et forme :SolidMasse moléculaire :610.492′-Thioadenosine
CAS :2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM againstFormule :C10H13N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :283.31DZD1516
CAS :DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFormule :C28H27F2N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :547.56JGK-068S
CAS :Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].Formule :C22H23BrFN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :488.35EGFR-IN-61
CAS :EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).Formule :C33H37ClN8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :629.15EGFR-IN-85
CAS :EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFRFormule :C26H30N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :486.57EGFR/CSC-IN-1
CAS :EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potentialFormule :C54H54Cl2FN7O7S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1067.08BMS-599626 Hydrochloride
CAS :BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formule :C27H28ClFN8O3Degré de pureté :99.98%Couleur et forme :SolidMasse moléculaire :567.01JND3229
CAS :JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Formule :C33H41ClN8O2Degré de pureté :98.75%Couleur et forme :SolidMasse moléculaire :617.18EGFR-IN-1 hydrochloride
CAS :EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formule :C28H31ClN6O4Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :551.04Ref: TM-T11157L
1mg62,00€5mg142,00€1mL*10mM (DMSO)190,00€10mg205,00€25mg319,00€50mg429,00€100mg587,00€200mg795,00€Sevabertinib
CAS :Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formule :C24H25ClN4O5Degré de pureté :99.81%Couleur et forme :SolidMasse moléculaire :484.93EGFR-IN-87
CAS :EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formule :C28H33N7O2Degré de pureté :98.64%Couleur et forme :SolidMasse moléculaire :499.61EGFR/ErbB-2 inhibitor-1
CAS :EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.Formule :C23H15ClFN3OS2Degré de pureté :98.93%Couleur et forme :SolidMasse moléculaire :467.97EGFR-IN-8
CAS :EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLCFormule :C32H23ClF3N7O4Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :662.02EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Couleur et forme :SolidEGFR-IN-38
CAS :EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96Andamertinib
CAS :Andamertinib is an EGFR inhibitor with antitumor activity.Formule :C31H36N8O3Couleur et forme :SolidMasse moléculaire :568.669EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formule :C31H30FN7OCouleur et forme :SolidMasse moléculaire :535.61Sacibertinib
CAS :Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64EGFR-IN-139
CAS :EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951Tyrphostin 63
CAS :Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183HER2-IN-7
CAS :HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55EGFR-IN-126
CAS :EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Couleur et forme :SolidEGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45JBJ-09-063
CAS :JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65EGFR-IN-160
CAS :EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27ES-072
CAS :ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Formule :C25H27F3N8O2Couleur et forme :SolidMasse moléculaire :528.53BPI-15086
CAS :BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formule :C29H33ClN8O4Couleur et forme :SolidMasse moléculaire :593.08Neptinib
CAS :Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Formule :C22H23ClFN5O2Couleur et forme :SolidMasse moléculaire :443.90HER2-IN-6
CAS :HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formule :C26H32N8O3Couleur et forme :SolidMasse moléculaire :504.58EG31
CAS :EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25EGFR-IN-149
CAS :EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formule :C12H14N4OS2Couleur et forme :SolidMasse moléculaire :294.4EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formule :C27H25N3O6SCouleur et forme :SolidMasse moléculaire :519.57LSD1/EGFR-IN-1
CAS :LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.
Formule :C21H20ClN3O4Couleur et forme :SolidMasse moléculaire :413.854HER2-IN-8
CAS :HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53EGFR-IN-159
CAS :EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.424EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formule :C26H28ClN3O4Couleur et forme :SolidMasse moléculaire :481.97Tesevatinib tosylate
CAS :Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formule :C31H33Cl2FN4O5SCouleur et forme :SolidMasse moléculaire :663.59Si306
CAS :Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formule :C25H26BrClN6OSCouleur et forme :SolidMasse moléculaire :573.94EGFR-IN-125
CAS :EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58NSC381467
CAS :NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34EGFR ligand-14
CAS :EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formule :C27H19ClFN3OCouleur et forme :SolidMasse moléculaire :455.91EGFR Ligand-Linker Conjugates 1
CAS :EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Formule :C37H47N9O3Couleur et forme :SolidMasse moléculaire :665.83EGFR-IN-35
CAS :EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96PROTAC Her3-binding moiety 2
CAS :PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Formule :C25H25N7O2Couleur et forme :SolidMasse moléculaire :455.51BML-265
CAS :BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23SORT1-IN-5
CAS :SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Formule :C19H31NO6SCouleur et forme :SolidMasse moléculaire :401.52EGFR-IN-132
CAS :EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formule :C27H31N7O3Couleur et forme :SolidMasse moléculaire :501.58EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Couleur et forme :SolidD-69491 hydrochloride
CAS :D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formule :C25H26Cl2FN7O3Couleur et forme :SolidMasse moléculaire :562.42HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formule :C17H18BrN5O2SCouleur et forme :SolidMasse moléculaire :436.33Tarloxotinib bromide
CAS :Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formule :C24H24Br2ClN9O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :681.77Ref: TM-T13088
1mg133,00€5mg268,00€10mg409,00€1mL*10mM (DMSO)414,00€25mg670,00€50mg888,00€100mg1.243,00€EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39JBJ-02-112-05
CAS :JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68Tyrosine Protein Kinase Substrate
CAS :Tyrosine Protein Kinase Substrate is a polypeptide molecule with the sequence RRLIEDNEYTARG.Formule :C66H109N23O23Masse moléculaire :1592.71EGFR-IN-147
CAS :EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275HER2-IN-21
CAS :HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447EGFR-IN-23
CAS :EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formule :C36H44BrN10O3PCouleur et forme :SolidMasse moléculaire :775.68EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23EGFR-IN-7
CAS :EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.
Formule :C32H41BrN9O2PDegré de pureté :95.32% - 99.64%Couleur et forme :SolidMasse moléculaire :694.6Nimotuzumab (powder)
CAS :Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Couleur et forme :LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Couleur et forme :Odour LiquidHMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Couleur et forme :Odour LiquidTLC9995-0188
CAS :Tyrosine-protein kinase ABL, IC50: 1500 nMFormule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331EGFRVIII Protein, Human, Recombinant (His & Avi)
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification.Couleur et forme :Lyophilized PowderMasse moléculaire :41.6 kDa (predicted). Due to glycosylation, the protein migrates to 68-80 kDa based on Tris-Bis PAGE result.Ref: TM-TMPK-00691
Produit arrêtéOlmutinib
CAS :Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormule :C26H26N6O2SDegré de pureté :99.14%Couleur et forme :SolidMasse moléculaire :486.59Duligotuzumab
CAS :Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Degré de pureté :95%Couleur et forme :LiquidEGFR-IN-82
CAS :EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/
Formule :C32H41BrN9O2PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :694.6YK-029A
CAS :YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.
Formule :C27H32N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :500.6EGFR-IN-122
CAS :EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.
Formule :C19H20N4O3Couleur et forme :SolidMasse moléculaire :352.39EGFR-IN-123
CAS :EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.
Formule :C24H27F3N6OCouleur et forme :SolidMasse moléculaire :472.51
